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Background: Infection of rabies virus (RABV) causes central nervous system (CNS) dysfunction and results in high
mortality in human and animals. However, it is still unclear whether and how CNS inflammation and immune
response contribute to RABV infection.
Methods: Suckling mice were intracerebrally infected with attenuated RABV aG and CTN strains, followed by
examination of chemokine or cytokine production, inflammatory cell infiltration and neuron apoptosis in the brain.
Furthermore, the suckling mice and adult mice that were intracerebrally infected with aG and the adult mice that
were intramuscularly infected with street RABV HN10 were treated with CCL5 antagonist (Met-CCL5) daily
beginning on day 2 postinfection. The survival rates and inflammation responses in the CNS of these mice were
analyzed.
Results: Excessive CCL5 in the CNS was associated with CNS dysfunction, inflammation, and macrophage or
lymphocyte infiltration after attenuated or street RABV infection. Administration of exogenous CCL5 induced
excessive infiltration of immune cells into the CNS and enhanced inflammatory chemokine and cytokine
production. Met-CCL5 treatment significantly prolonged survival time of the suckling mice inoculated with aG and
adult mice infected with aG and HN10.
Conclusions: These results suggest that CCL5 in the CNS is a key regulator involved in inducing rabies encephalomyelitis.
Furthermore, treatment with the CCL5 antagonist Met-CCL5 prolongs survival time of the mice infected with
attenuated or street RABVs, which might represent a novel therapeutic strategy to ameliorate RABV infection.Background
Rabies virus (RABV) is a highly neurotropic virus that
causes lethal central nervous system (CNS) disease in many
species of mammals including humans [1]. Although rabies
has been well controlled in the United States and other de-
veloped countries by vaccination in animals, it is still a pub-
lic health threat, causing more than 55,000 human deaths
worldwide each year [2]. Furthermore, no therapy has
proved effective to cure rabid patients once rabies enceph-
alitis develops or once the clinical symptoms appear.* Correspondence: qtang04@sina.com; hongyanwang@sibcb.ac.cn
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unless otherwise stated.Immune responses and CNS dysfunction are two main
factors to be considered during RABV infection. Although
RABV infection is invariably lethal in the absence of pro-
tective immune responses, several studies have argued that
excessive immune responses may not always be beneficial
for RABV infection. Attenuated RABV activates innate
immune responses and induces extensive inflammation,
apoptosis and neuronal degeneration in the CNS in ex-
perimental animals [3-6]. Moreover, the expression of the
genes involved in innate immune and antiviral responses
were highly upregulated after infection with attenuated
RABV, especially those related to the alpha/beta interferon
(IFN-α/β) signaling pathways, inflammatory cytokines
and chemokines, including interleukin-6 (IL-6), IL-1α/β,
IL-10, CXCL10/IP-10 and CCL5/RANTES [7-9]. How-
ever, it has been shown that overexpression of these che-
mokines (such as CXCL10 and CCL5) is closely correlated
with severe enhancement of blood-brain barrier (BBB)Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of inflammatory cells in the CNS, which contributes to the
increased pathogenicity in neurological diseases [10-12].
Most street RABVs evade the host innate immune sys-
tem and fail to induce protective virus neutralizing anti-
body (VNA) responses [13-16]. However, in some murine
or dog experimental models infected with street RABVs, T
cell and mononuclear cell infiltration in the CNS have
been observed together with severe encephalitis in the late
stage of infection [16-18]. Although inflammatory re-
sponse in the early stage of infection is important for
clearance of RABV from the CNS [19], there is no evi-
dence to suggest that severe inflammation in the late stage
is beneficial to or impedes the development of the disease.
Chemokines have been originally identified as chemo-
tactic and pro-adhesive cytokines by their interaction
with G protein-coupled receptors. CCL5 (also termed as
RANTES) is a β chemokine and induces leukocyte mi-
gration by binding to CCR1, CCR3 or CCR5 [20,21]. An
elevated level of CCL5 has been associated with a variety
of inflammatory disorders [22,23]. As one of the CCL5
receptors, CCR5 also has a significant role in various dis-
eases, such as AIDS [24], arthritis [25],Toxoplasma gondii
infection [26], West Nile virus infection [27] and respira-
tory virus infection [28]. Met-CCL5, an N-terminally
modified human CCL5, has been previously shown to in-
hibit activity at two rodent chemokine receptors CCR1
and CCR5 [29]. Targeting CCL5 or CCR5 with antagonists
may have potential therapeutic usage to alleviate symp-
toms of these diseases [30,31].
In this study, mice infected with attenuated RABVs de-
veloped excessive inflammation in the CNS. CCL5 was the
highest virus-induced chemokine among 40 inflammatory
cytokines and chemokines, which promoted migration of
macrophages and T cells into the CNS. Excitingly, admin-
istration of the CCL5 antagonist, Met-CCL5, alleviated ra-
bies clinical symptoms and prolonged the survival time of
the sucking mice infected with attenuated RABV or adult
mice infected with attenuated or street RABVs. Met-CCL5
treatment significantly reduced pro-inflammatory chemo-
kine or cytokine production in the CNS after RABV infec-
tion. The findings suggest that Met-CCL5 might be used
as a novel therapeutic reagent to prolong the survival time
after RABV infection.
Methods
Animals and virus strains
Suckling mice (7-day-old) and adult mice (6-week-old)
were purchased from the Institute of Laboratory Animal
Medicine at the Chinese Academy of Medical Sciences
(CAMS & PUMC, Beijing, China) and housed in the
BSL-3 facility of the Veterinary Research Institute at the
Academy of Military Medical Sciences. All procedures
were conducted in accordance with the guidelines forthe Medical Laboratory Animal (1998) from Ministry of
Health, China. All animal experiments were carried out
as approved by the Institutional Animal Care and Use
Committee, Chinese CDC (permission number: 12-0121).
Three strains of rabies viruses isolated in China were used
in this study, including aG [32], CTN [33] and HN10 [34].
The background for isolation, hereditary traits and gen-
omic information of these strains were well documented.
The parental virus of the aG strain was isolated from the
brain of a rabid dog in 1931, and it was attenuated to a
fixed strain by 30 passages in rabbits, 55 passages in pri-
mary hamster kidney cells (PHKC), and several passages
in guinea pigs and PHKC [32]. The aG strain was patho-
genic for adult mice by intracerebral (i.c.) inoculation, but
non-pathogenic through peripheral infection; it was used
as a vaccine in 1981 in China [32]. The parental virus of
the CTN strain was isolated from a rabid patient and at-
tenuated by passaging in mice and human diploid cells.
The pathogenic-related amino acid residue in position 333
of glycoprotein was mutated from arginine (R) to glutam-
ine (Q). This CTN strain has been approved as a vaccine
strain by the World Health Organization (WHO) since
1983 [33]. The HN10 strain was a street virus strain iso-
lated from a rabid patient in China in 2006 [34].
Virus infection and exogenous injection of CCL5 or
Met-CCL5
Suckling mice were i.c. infected with aG or CTN. Adult
mice were i.c. infected with aG or intramuscularly (i.m.) in-
fected with HN10 (that is, the muscles of the right thigh)
(5.6 × 103 FFU, fluorescent focus forming unit; 25 μl in
DMEM medium) (n = 10). To assess migration and apop-
tosis of immune cells infiltrating the CNS, suckling mice
were i.c. injected with CCL5 (5 μg/ml, 25 μl), and the same
volume of sterile PBS was used for mock controls. For
Met-CCL5 treatment, suckling mice were intraperitoneally
(i.p.) administrated daily with Met-CCL5 (100 μg/ml,
100 μl) from day 0 postinfection (p.i.) and adult mice were
i.p. injected daily with high dose (200 μg/ml, 100 μl), low
dose (20 μg/ml, 100 μl) of Met-CCL5, or the control re-
agent (random sequence of the amino acids from Met-
CCL5; 200 μg/ml, 100 μl) beginning on day 2 p.i.. Recom-
binant carrier-free Met-CCL5 was purchased from R&D
(R&D, Minneapolis, MN, USA). Met-CCL5 was derived
from E.coli and contained 69aa from Ser24 to Ser91
with an N-terminal Met. The carrier-free control peptide
(purity ≥95%) with the same length but random sequence of
amino acids from Met-CCL5 was chemically synthesized by
Hanhong Chemical Co. Ltd (Hanhong, Shanghai, China).
Preparation of immune cells in spleen or central nervous
system
Spleens from RABV-infected mice were homogenized and
filtered through a 70-μm nylon cell strainer (Corning,
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After red blood cells were removed with a lysing solu-
tion, cells were prepared for culturing or staining. To
isolate immune cells infiltrating the CNS, mouse brains
were removed and homogenized using digestion buffer
(HBSS containing 0.05% collagenase IV and 10 μg/ml
DNase I) and then filtered through a 70-μm nylon cell
strainer (Corning, Union City, CA, USA). After digest-
ing at room temperature for 20 minutes, the homoge-
nates were allowed to settle vertically for another
20 minutes [35]. The clear supernatant was collected
and centrifuged, and the single cell solution was pre-
pared for analysis by flow cytometry thereafter.
Flow cytometry
Antibodies (Abs) for flow cytometry were purchased from
eBioscience (anti-B220, −CD3, −CD4, −CD11b, −F480,
and − CD8), BD Biosciences (anti-CCR5, −Annexin V,
and -BrdU), and Cell Signaling Technology (anti-Caspase-
3 Asp175). Staining processes were performed according
to the manufacturer’s instruction. Briefly, for cell surface
straining, cells were blocked with Fc γ MAb (0.5 μg/ml)
for 30 min at 4°C. After being washed with PBS, cells were
stained with antibodies against B220, CD3, CD4, CD11b,
F480, CD8 or CCR5 for 30 min on ice with gentle shaking.
For cell apoptosis analysis, fresh cells were stained with
anti-Annexin V antibody and propidium iodide (PI), while
pre-fixed and permeated cells were stained using anti-
caspase-3 antibody. For BrdU incorporation assay, the
RABV-infected mice (n ≥3) were i.p. injected with BrdU
(10 mg/ml, 100 μl) for 24 hours (hrs); cells from brains
were then collected. After being stained with cell surface
markers for 30 min on ice, the cells were stained with
anti-BrdU antibody according to the manufacturer’s in-
struction. Samples were processed using FACSCalibur
or Accuri C6 (BD Biosciences, San Jose, CA, USA), and
data were analyzed with the FlowJo software (Tree Star,
Ashland, OR, USA).
Western blot
Western blot was performed using the following primary
antibodies: phospho-Akt (Ser 473) and phospho-Fak
(Tyr 925) (Cell Signaling Technology, Danvers, MA,
USA). Briefly, splenocytes from the RABV-infected and
mock-infected mice were harvested, and splenocytes
from the mock-infected mice were stimulated with or
without 60 ng/ml CCL5 at 37°C for 5 min. After being
washed with PBS, the cells were lysed using SDS-loading
buffer and boiled for 10 min. Lysates were separated by
sodium dodecyl sulfate polyacrylamide gel electrophor-
esis (SDS-PAGE) and transferred thereafter to a nitrocel-
lulose membrane. After being blocked in TBST with 5%
BSA for 1 hour (h), the membrane was incubated with pri-
mary antibodies overnight at 4°C, followed by incubationwith horseradish peroxidase-labeled secondary antibody.
Detection was performed with ECL substrate (Thermo
Scientific, West Palm Beach, FL, USA).
Inflammation antibody array assay
Mouse inflammation antibody array G (RayBiotech,
Norcross, GA, USA) was used to determine the protein
expression levels of various cytokines and chemokines
in the brain samples. Briefly, proteins were extracted
from brains of the moribund mice infected with aG,
CTN or HN10 (n ≥3 in each group). The array was in-
oculated with 50-μg proteins in 100 μl of the supplied
buffer and then treated with biotin-conjugated anti-
bodies for 2 h. After being washed, the array was incu-
bated with Alexa Flour 555-conjugated streptavidin for
2 h at room temperature, and the images were visualized
using an Axon GenePix 4300A laser scanner (Molecular
Devices, Sunnyvale, CA, USA).
Quantitative real-time PCR
The relative mRNA expression levels of IL-1β, IL-6, IL-
12, IL-17, CCL3, CCL5 and virus nucleoprotein were
measured by quantitative real-time PCR (qRT-PCR).
Briefly, total RNA was isolated from brains of the
RABV-infected mice using TRIzol reagent (Invitrogen,
Grand Island, CA, USA). cDNAs were synthesized from
mRNA by Ready-To-Go You-Prime First-Strand Beads
(Amersham Biosciences, Piscataway, NJ, USA) using d
(N)6 as primers. qRT-PCR was performed using SYBR
Green real-time PCR master mix on the CFX96 system
(Bio-Rad, Hercules, CA, USA). To examine virus replica-
tion in brains, the mRNA levels of virus nucleoprotein
were measured by qRT-PCR using specific primers to
detect N protein. The mRNA copy numbers were nor-
malized to the housekeeping gene β-actin.
Preparation of bone marrow-derived macrophages
Bone marrow-derived macrophages (BMM) were gener-
ated using L929-cell conditioned medium (LCCM) as a
source of granulocyte/macrophage colony-stimulating
factor. Briefly, bone marrows were removed from tibias
and femur bones of 8-week-old mice. Following red
blood cell lysis and washing, cells were plated in DMEM
medium (Invitrogen, Grand Island, CA, USA) supple-
mented with 10% fetal calf serum (CSF), 1% strepto-
mycin/penicillin, and 30% LCCM. On day 7, BMMs
were treated for 6 hrs with CCL5 (60 ng/ml), poly (I:C)
(polyinosinic-polycytidylic acid), or poly (I:C) and CCL5
with or without Met-CCL5. The relative mRNA levels of
cytokines or chemokines were evaluated by qRT-PCR.
Transwell migration assay
Splenocytes were isolated from the RABV-infected mice
and their migration ability with or without CCL5
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Briefly, 600 μl RPMI1640 medium with or without
100 ng/ml CCL5 was added into a 24-well plate, and
then splenocytes (0.5million/100 μl) were placed in the
transwell inserts (Corning, Union City, CA, USA). The
transparent polyester membranes of the inserts were
immersed in the RPMI medium. After being incubated
at 37°C for 6 hrs, the cells that had migrated through
the polyester membrane into the RPMI medium were
collected and counted under an Olympus CK40 light
microscope (Olympus, Tokyo, Japan).
Preparation and staining of brain section
RABV-infected mice were euthanized and perfused with
PBS followed by 4% paraformaldehyde fixation. The
brains were removed and fixed in 4% paraformaldehyde
at 4°C for 24 hrs and then immersed in a 10% sucrose
solution at 4°C for 48 hrs. Coronal frozen sections of
brain tissue (20 μm) were cut on a Leica CM1900 micro-
tome (Leica, Wetzlar, Germany). Sections were stained
with cresyl violet to examine the pathological changes of
neurons. To detect activated caspase-3, brain sections
were incubated with PBS/0.2% Triton for 5 min, and
then blocked with PBS containing 5% donkey serum and
0.1% Tween 20 for 2 hrs. They were then stained with
rabbit anti-active caspase-3 polyclonal antibody (Pro-
mega, Madison, WI, USA) overnight at 4°C. After being
washed, brain sections were incubated with Cy3-donkey
anti-rabbit IgG antibody (Jackson Laboratories, West
Grove, PA, USA) for 2 hrs at room temperature. For ter-
minal deoxynucleotidyl transferase dUTP nick end label-
ing (TUNEL) staining, the frozen tissue sections were
stained according to the manufacture’s protocols for
DeadEnd Colorimetric TUNEL System kit (Promega, WI,
USA). The average number of apoptotic cells in different
regions of hippocampus (CA1, CA3 and DG) was quanti-
fied. To detect immune cell infiltration in the brain, T
lymphocytes, macrophages, and activated microglia were
stained with Alexa Fluor 488-anti-mouse CD3 monoclo-
nal antibody (17A2), anti-mouse integrin αM/CD11b anti-
body, and Northernlights NL557 fluorescent secondary
antibody (R&D, Minneapolis, MN, USA), respectively.
The numbers of infiltrated CD3+ T cells in the brain were
counted under 10× magnification for each slide. Images
were taken from an Olympus FV500 confocal microscope
(Olympus, Tokyo, Japan).
Statistical analysis
Statistical significances between different groups were
analyzed using a two-tailed Student’s t-test or two-way
ANOVA, and statistical significance of survival rates was
determined by the log rank test and Kaplan-Meier sur-
vival analysis. P <0.05 was considered statistically signifi-
cant (*P <0.05; **P <0.01; ***P <0.001).Results
Rabies virus infection induces high mortality and
excessive inflammation in the central nervous system of
suckling mice
To identify the key immune effectors that contribute to
the development of CNS inflammation and lethal RABV
infection, suckling mice were i.c. infected with attenu-
ated RABV strains, including CTN and aG. All the mice
developed neurological symptoms, such as agitation,
fury, and paralysis of hind limbs within a week p.i.. As
shown in Figure 1A, 80% and 50% of suckling mice were
dead at day 6 p.i. with aG and CTN, respectively. Also, 1
log more RABV N mRNA was detected in aG-infected
mice than in CTN-infected mice (Figure 1B). To investi-
gate whether the pathogenicity of these attenuated RABVs
was related to overreaction of the host immune system
and extensive inflammatory response in the CNS, RayBio™
Mouse Inflammation Antibody Array G was used to screen
the protein expression levels of more than 40 inflammatory
molecules, including cytokines, chemokines and growth
factors. The inflammatory molecules that upregulated in
varying levels in aG- or CTN-infected brains were listed in
Figure 1C. There were 11 cytokines or chemokines that
were enhanced at both the onset and late stages of RABV
infection, and CCL5 was expressed with the highest
level being 33.7 and 15.8 in aG- and CTN-infected
mice, respectively (Figure 1D). Furthermore, the anti-
body array was randomly confirmed by qRT-PCR, and
the results showed that pro-inflammatory chemokines
including CCL5 and CCL2 (Figure 1E) and cytokines
including IL-6, IL-1β, IL-12, and IL-17 (Figure 1F)
were significantly enhanced after infection with aG and
CTN. A previous microarray screening analysis on at-
tenuated RABV infected mice was based on 22,626
mouse genes and showed that except for the induction
of genes in the IFN-α/β signaling pathway, genes en-
coding inflammatory cytokines and chemokines were
highly upregulated including CCL5 [6]. Another study,
which used the Milliplex MAP 30-plex premixed mouse
cytokine/chemokine magnetic bead panel, also proved
that CCL5 was highly upregulated in attenuated rabies
virus-infected mice [18]. Together, our and others’ studies
suggested that attenuated RABV-infected mice induced a
strong inflammatory immune reaction in the CNS.
Attenuated rabies virus infection increases infiltration of
immune cells into the central nervous system
To investigate whether excessive chemokines in the
CNS affected recruitment of macrophages and T lym-
phocytes during RABV infection, brain infiltration of
lymphocytes (BILs) were isolated and analyzed by flow
cytometry. The infiltrated macrophages and activated
resident microglia had been suggested to provide the
first line of defense against infection in the CNS, which
Figure 1 Rabies virus (RABV) infection induces high mortality and excessive inflammation in the central nervous system of suckling
mice. Suckling mice were intracerebrally (i.c.) infected with aG or CTN (5.6 × 103 FFU), and (A) the survival rates were monitored (n = 10 in each
group). (B) The relative mRNA levels of RABV N protein were determined in aG- and CTN-infected mice on day 5 and day 7 postinfection (p.i.).
(C) On day 7 p.i., the expression profiles of various inflammatory proteins in brain samples were evaluated by RayBio™ Mouse Inflammation
Antibody Array G. (D) The protein levels of inflammatory molecules that were enhanced over 1.5-fold in the brain samples infected with aG and
CTN are listed (n = 3). The relative mRNA levels of CCL5, CCL2 (E), IL-6, IL-1β, IL-12, IL-17 (F) in brain samples were verified by quantitative reverse
transcriptase PCR (qRT-PCR) after aG and CTN infection. Data were presented as means ± SD (*P <0.05; **P <0.01; ***P <0.001).
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ously described [11,36]. As shown in Figure 2A, the
percentages of infiltrated macrophages and activated
microglia were significantly increased in aG- or CTN-
infected mice when compared to those in mock-infected
mice; the in vivo BrdU incorporation assay also
showed that CD11bhiF4/80+ BILs were highly prolifer-
ated in mice infected with CTN (Figure 2B). This dem-
onstrated that macrophages infiltrated the CNS, and
resident microglia were activated in response to the at-
tenuated RABVs infection. Similarly, CD3+, CD4+ and
CD8+ T cells infiltrated the brains examined by flow
cytometry (Figure 2C). This was confirmed by immu-
nohistochemistry (IHC) staining of the infected brain
tissue sections using anti-CD3 antibodies (Figure 2D),
suggesting that T lymphocytes also infiltrated the CNS
after attenuated RABV infection.CCL5/CCR5 is essential for mediating immune cell
infiltration in the central nervous system of rabies
virus-infected mice
CCL5/CCR5 has been well demonstrated to activate several
types of immune cells and guide them to specific homing
into target organs in some diseases [37,38]. Therefore,
further investigation needs to determine whether CCL5/
CCR5 mediates migration of the immune cells into the
CNS during RABV infection. The increase in expression
levels of surface CCR5 in macrophages or splenocytes in
the aG- or CTN-infected mice was 1.5 to 5-fold that ob-
served in the mock-infected mice (Figure 3A). The mRNA
levels of CCR5 in the CNS were also upregulated in
aG-infected mice compared to those levels in mock-
infected mice (Figure 3B). Next, the chemotactic activity
of splenocytes isolated from RABV-infected mice was
assessed in response to CCL5 stimulation by Transwell™
Figure 2 Attenuated rabies virus (RABV) infection increases infiltration of immune cells into the central nervous system (CNS). Suckling
mice were intracerebrally (i.c.) infected with aG and CTN, and brains and spleens were harvested on day 7 postinfection (p.i.) (n ≥3, mean ± SD).
The percentages of CD11bhi F4/80+ cells (A), CD3+, CD4+ and CD8+ T lymphocytes (C) from brain infiltration of lymphocytes (BILs) were measured by
flow cytometry. (B) Suckling mice were i.c. infected with CTN (5.6 × 103 FFU) or PBS and then intraperitoneally (i.p.) injected with BrdU on day 5 p.i..
BILs in the brain were isolated and subjected to flow cytometry analysis. (D) Number of CD3+ T cells infiltrated into different regions of the brain,
including cerebral cortex, hippocampus, thalamus and hypothalamus, were quantified by immunohistochemistry (IHC) staining. Data were presented
as means ± SD (**P <0.01; ***P <0.001).
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enhancement, splenocytes isolated from aG-infected
mice migrated more efficiently through the transparent
polyester membrane in response to CCL5 stimulation
(Figure 3C), which indicated that CCL5/CCR5 inter-
action promoted immune cell migration during RABV
infection. Furthermore, the phosphorylation levels of
Fak and Akt, two critical effectors for cell migration,
were analyzed. After CCL5 stimulation, splenocytes
isolated from mock-infected mice increased the phos-
phorylation levels of Fak and Akt (Figure 3D, left
panel), which is in agreement with a previous study
[39]. Interestingly, the phosphorylation levels of Fak
and Akt were significantly enhanced in splenocytes
after aG infection (Figure 3D, right panel). Together,
these data suggest that CCR5 expression levels in im-
mune cells increased after RABV infection, which in-
duce Fak and Akt phosphorylation to promote cell
migration in response to enhanced CCL5 in the CNS.
To further confirm that CCL5 was one critical immune
regulator recruiting macrophages or T cells into brains,
exogenous CCL5 was i.c. injected into mice. Resting
microglia were identified as the CD11bintF4/80+ popula-
tion, and the infiltrated macrophages and activated micro-
glia were labeled as the CD11bhiF4/80+ population. Asshown in Figure 3E, resting microglia existed in mice
treated with either PBS or exogenous CCL5, whereas
CD11bhiF4/80+ macrophages and activated microglia
were significantly higher in the mice treated with exogen-
ous CCL5. This suggests that exogenous CCL5 in the
brain activates resting microglia or recruits macrophages
into the CNS. Moreover, the percentages of CD3+,
CD4+ and CD8+ T cells increased substantially more in
mice treated with CCL5 than in those treated with PBS
(Figure 3F). This result was consistent with the enhanced
infiltration of CD3+ T cells into the CNS after RABV
infection (Figure 3G).
Exogenous CCL5 treatment and rabies virus infection
enhance neuron apoptosis in the central nervous system
It was previously reported that encephalitis induced by
attenuated RABVs could induce neuron damage or
apoptosis, which plays an important role in the patho-
genesis of RABV infection [5]. Since neurons, astrocytes
and oligodendroglia in the CNS have limited capacity for
self-renewal, fatal outcome or dysfunction may be shown
when these cells are severely damaged after RABV infec-
tion. As shown in Figure 4A, the percentages of early
apoptosis (AnnexinV+PI−, 27.9% versus18.3%) and late
apoptosis/necrosis (AnnexinV+PI+, 5.61%versus 3.11%)
Figure 3 CCL5/CCR5 is essential to mediate immune cell infiltration in the central nervous system (CNS) of aG- or CTN-infected mice.
(A) The percentages of CCR5+ cells in CD11b+ macrophages from brain infiltration of lymphocytes (BILs) or splenocytes in mice infected with
rabies viruses (RABVs) were assessed using flow cytometry. (B) The relative mRNA level of CCR5 was analyzed in mock- or aG-infected brain samples
on day 5 postinfection (p.i.). (C) The number of migrated splenocytes in response to CCL5 (100 ng/ml) was analyzed using in vitro transwell assay.
(D) The phosphorylation of Fak and Akt in splenocytes from mock- or aG-infected mice was determined by western blot, while exogenous CCL5-
stimulated splenocytes were used as a positive control. (E and F) Suckling mice were intracerebrally (i.c.) injected with exogenous CCL5 (25 μl,
5 μg/ml). On day 1 p.i., cells isolated from brains were collected to assess the percentages of F4/80+CD11bhi microglia/macrophages, CD3+,
CD4+ and CD8+ T lymphocytes using flow cytometry. (G) The percentage of infiltrated CD3+ T cells in the brain of mock- or CTN-infected mice
was analyzed using flow cytometry.
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than in those injected with PBS. Next, the degree of
neuron damage after aG and CTN infection was further
assessed. Mouse brain frozen sections were stained with
cresyl violet, TUNEL and activated caspase-3 to analyze cy-
topathology and cell apoptosis after aG and CTN infection.
Compared to mock-infected mice (Figure 4B, a/d), more
severe neuronal cytopathology in the cerebral cortex and
hippocampus were observed in aG- and CTN-infected
mice (Figure 4B, b/e and c/f), characterized by irregular
nuclear chromatin condensation, vacuolation and loss of
neurons. Moreover, significantly more apoptotic DNA frag-
ments were observed in the hippocampus (Figure 4C),
hypothalamus, cerebellum and brain stem (Figure 4D) in
aG- and CTN-infected mice than in mock-infected mice.
In addition, the enhanced amount of cleaved/activated
caspase 3 was observed in the CNS in aG- and CTN-
infected mice (Figure 4E). These results suggest that CCL5plays a critical role in inducing neuron apoptosis in the
CNS in response to the attenuated RABV infection.
Met-CCL5 treatment reduces central nervous system
inflammation and prolongs survival time after rabies virus
infection
Met-CCL5, widely used as a CCL5 antagonist, could
competitively bind to CCR5 and CCR1 to inhibit func-
tion and signaling pathways evoked by CCL5 [29,31].
Since RABV-induced CCL5 or exogenous administration
of CCL5 could increase the numbers of immune cells in-
filtrating the CNS and enhance neuron apoptosis, there
was an investigation as to whether in vivo administration
of Met-CCL5 could lessen the severity of RABV infec-
tion. Met-CCL5 (10 μg/mouse) or PBS was i.p. injected
daily into aG-infected suckling mice. Compared with
PBS-treated mice, Met-CCL5 treated mice showed sig-
nificantly prolonged survival time with an extra 2 days
Figure 4 Exogenous CCL5 treatment and rabies virus infection enhance neuron apoptosis in the central nervous system. Mice were
intracerebrally (i.c.) infected with PBS or exogenous CCL5 (25 μl, 5 μg/ml). (A) On day 1 postinfection (p.i.), single cell suspension was prepared
from the brains and stained with propidium iodide (PI) and AnnexinV to analyze cell apoptosis by flow cytometry. (B) Suckling mice infected with
aG and CTN (5.6 × 103 FFU) were euthanized, and brains were removed to prepared frozen section on day 5 p.i.. Pathological changes of neurons,
including irregular nuclear chromatin condensation, vacuolation, and neuron necrosis in cerebral cortex and hippocampus, were observed by cresyl
violet staining (Magnification: 40×). (C and D) Brain sections were subjected to terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
staining, and the TUNEL-staining positive cells were quantified (n = 3). (E) Cleaved caspase-3 was stained with caspase-3 antibody (red), and the cell
nuclei were stained with DAPI (blue). Image magnification: a-f (60×), g-i (20×). Data were presented as means ± SD (**P <0.01; ***P <0.001).
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IL-6 (Figure 5B) and RABV N protein (Figure 5C) were
significantly downregulated in Met-CCL5 treated mice,
suggesting that Met-CCL5 could reduce the production of
pro-inflammatory cytokines and chemokines and prolong
the survival time of attenuated RABV-infected suckling
mice. To further assess how CCL5 and Met-CCL5 directly
affect macrophages in regard to the production of CCL5
and pro-inflammatory cytokines, bone marrow-derived
macrophages (BMMs) were treated with several stimuli
in vitro. BMMs stimulated with CCL5 significantly in-
creased the mRNA levels of CCL5, IL-6 and TNF-α
(Figure 5D). It has been suggested that poly (I: C), a
synthetic mimic of dsRNA, has been used extensively
as a TLR3 ligand to mimic RNA virus infection and ac-
tivate the TLR3 signaling pathway for subsequentexpression of cytokines and chemokines, including CCL5
and IL-6 [40,41]. It was observed that CCL5 and IL-6 were
upregulated in poly (I:C) treated BMMs and were further
enhanced when BMMs were treated with poly (I:C) plus
CCL5. Interestingly, Met-CCL5 treatment significantly re-
duced poly (I:C) and CCL5-induced CCL5 and IL-6 pro-
duction in BMMs, which were comparable to those in
poly (I:C)-stimulated BMMs (Figure 5E).
Met-CCL5 treatment prolongs survival time of the mice
infected with attenuated and street rabies viruses
To further assess whether Met-CCL5 treatment pro-
tected adult mice from aG infection in vivo, a control
protein containing the same amino acids as Met-CCL5
with a random sequence was synthesized and used as a
negative antagonist control. Adult mice were i.c. infected
Figure 5 Met-CCL5 treatment reduces the central nervous system inflammation after rabies virus infection. Suckling mice were
intracerebrally (i.c.) infected with aG (5.6 × 103 FFU) followed by daily intraperitoneal (i.p.) administration with PBS or Met-CCL5 (100 μg/ml,
100 μl). (A) The survival rates in each group were recorded. (B) On day 5 postinfection (p.i.), the relative mRNA levels of CCL5 (B, left panel) and
IL-6 (B, right panel) and RABV N protein (C) in the brains were quantified by quantitative reverse transcriptase PCR (qRT-PCR). (D) Bone marrow-
derived macrophage (BMM) were treated with CCL5 (60 ng/ml, 6 hrs), and the relative mRNA levels of CCL5, IL-6 and TNF-α were measured by
qRT-PCR. (E) BMMs were stimulated for 6 hrs with poly I:C alone, in the absence or presence of CCL5 or CCL5 and Met-CCL5. The relative mRNA
levels of CCL5 and IL-6 were determined using qRT-PCR. Data were presented as means ± SD (*P <0.05; **P <0.01; ***P <0.001).
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tagonist daily from day 2 p.i.. All mice treated with the
negative antagonist died within 8 days after infection
with aG, whereas the mice treated with the high or low
dose of Met-CCL5 exhibited prolonged survival time for
an extra 3 days (P = 0.002 or P = 0.0014) (Figure 6A). No
significant differences in survival time were observed be-
tween high and low doses of Met-CCL5-treated mice.
Collectively, these data suggest that Met-CCL5 might
compete with excessive CCL5 in the CNS to reduce in-
flammation and protect adult mice from attenuated
RABV infection.
To mimic RABV infection in a natural route, adult
mice were i.m. infected with street RABV strain HN10.
First, we assessed whether excessive inflammatory cyto-
kines and chemokines existed in the CNS of the HN10-
infected adult mice. As shown in Figure 6B, the mRNA
levels of CCL5, CCL3, IL-12 and IL-6 were significantly
upregulated in the brain of the HN10-infected adult
mice. Since Met-CCL5 could reduce inflammation andprolong survival time in the aG-infected suckling and
adult mice, we suspect and further investigate whether
Met-CCL5 treatment could also protect adult mice from
the street RABV infection via an i.m. route. Adult mice
were i.m. infected with HN10 and then injected with
Met-CCL5 daily i.p. from day 2 p.i. (high dose: 20 μg/
mouse or low dose: 2 μg/mouse). As shown in Figure 6C,
Met-CCL5 significantly prolonged the survival time of
HN10-infected adult mice compared to the control
mice. In the early days of infection (that is, day 0 to day
14), Met-CCL5 treatment substantially increased survival
rates of these infected mice compared to control
protein-treated mice (that is, 80% versus 30% survival
rates at day 14). Similar to the effect observed in the aG-
infected suckling mice, there was no significant differ-
ence between high dose and low dose of Met-CCL5
treated groups. Importantly, the mRNA levels of CCL5,
IL-6 and TNF-α were significantly reduced in the CNS
of Met-CCL5 treated mice compared to the CNS in con-
trol mice (Figure 6D), and no significantly reduced virus
Figure 6 Met-CCL5 treatment prolongs the survival time in adult mice after rabies virus infection. The 6-week-old ICR mice (n≥ 3) were
intramuscularly (i.m.) infected with HN10 (5.6 × 103 FFU), and the relative mRNA levels of CCL5, IL-12, CCL3, IL-6 were evaluated by quantitative
reverse transcriptase PCR (qRT-PCR) (B). The 6-week-old ICR mice were intracerebrally (i.c.) infected with aG or intramuscularly (i.m.) infected with
HN10 followed by intraperitoneal (i.p.) administration of 100 μl Met-CCL5 at a concentration of 200 μg/ml or 20 μg/ml and 100 μl synthesized
random disordered Met-CCL5 (200 μg/ml) as negative controls from day 2 postinfection (p.i.). Mice were monitored for 21 days, and the survival
rate in the aG-infected group (A) and in the HN10 infected group (C) were recorded (n = 10; *P <0.05; **P <0.01; ***P <0.001). When the negative
control mice infected with HN10 showed clinical signs, Met-CCL5 treated mice and control mice were euthanized at the same time, brains were
removed, and these brains were subjected to analysis for pro-inflammatory chemokine/cytokine expression and virus load using qRT-PCR (D).
Data were presented as means ± SD (*P <0.05; **P <0.01; ***P <0.001).
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the protective role of Met-CCL5 in the early days of in-
fection, over 50% of Met-CCL5 treated adult mice still
died after 19 days p.i. (Figure 6C), suggesting that add-
itional treatment might be combined with Met-CCL5 to
improve anti-RABV efficacy.
Discussion
RABV is a highly neurotropic virus inducing acute infec-
tion in the CNS. Chemokines are now recognized as
critical regulators of leukocyte trafficking in the CNS,
and numerous studies have revealed that resident cell
populations of the CNS are able to synthesize and se-
crete a variety of chemokines. Neurons, microglia and
astrocytes are the primary sources of chemokines follow-
ing infection with a wide range of neurotropic viruses,
including RABV [42], WNV [43], and herpes simplex
virus 1 (HSV1) [44]. In vitro studies have highlighted that
infection of neurons with RABV results in robustproduction of chemokines [42]. In this study, we screened
the expression levels of 40 inflammatory molecules in the
CNS and demonstrated that CCL5 is the most signifi-
cantly upregulated chemokine in response to aG and
CTN infection in suckling mice, which suggested chemo-
kine CCL5 is one key immune regulator during RABV
infection.
Chemokines are critical mediators of neuropathology
during viral infections in the CNS, either by attracting
pathogenic inflammatory cells or directly mediating neuro-
toxicity and cell death. Chemokines regulate infiltration of
immune cells to the CNS after viral infection by enhancing
blood-brain barrier (BBB) permeability [45]. These im-
mune cells release additional chemokines, such as CCL5,
to further recruit macrophages, monocytes and T cells,
consequently increasing the severity of demyelination [23].
A previous study showed that recombinant RABV express-
ing CCL5 or IP-10 increased pathogenicity with excessive
infiltration of inflammatory cells into the CNS [11]. In this
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vated microglia and neuron apoptosis was detected in mice
infected with attenuated RABVs, which is in agreement
with what others have reported [5]. Moreover, our in vivo
and in vitro data suggested that CCL5 played an essential
role in enhancing trafficking of immune cells in the CNS
during RABV infection.
CCL5 belongs to the CC family of chemokines and
plays an important role in recruiting T cells, macro-
phages and monocytes to the site of inflammation by
interacting with the specific G protein-coupled receptors
CCR1, CCR3 and CCR5 [20,21]. The binding of CCL5
and its receptors CCR5 activates a series of downstream
effectors that facilitate leukocyte trafficking into the
CNS [37]. Although immune cell infiltration and anti-viral
activity is requisite for viral clearance, excessive accumula-
tion of leukocytes within the CNS results in neuropathol-
ogy [11]. Met-CCL5 is a CCL5 receptor antagonist, which
is used extensively to block the pathogenic effects of
CCL5 and attenuate CCR5-mediated inflammatory pro-
cesses during the development of arthritis, colitis, airway
inflammation, allograft rejection and chronic liver diseases
[46-50]. Moreover, CCR5 is involved in HIV entry to tar-
get cells, so CCR5 antagonists have been successfully
tested in phase III studies in patients with HIV infection.
In this study, i.p. administration of CCL5 antagonist Met-
CCL5 significantly reduced CCL5 and IL-6 in aG-infected
suckling mice. Other studies have shown that street
RABVs also induce a strong inflammatory response in
adult mice or dogs at the late stage of the infection
[16,18]. Since upregulated inflammatory cytokines and
chemokines were also observed in adult mice infected
with street RABV by i.m. route, an investigation as to
whether Met-CCL5 was protective in these mice was car-
ried out. Indeed, Met-CCL5 significantly protected adult
mice from the infection of the street strain HN10, espe-
cially at the early stage of infection. According to previous
studies, pretreatment with Met-CCL5 at doses of 0.1 and
1 μg/mouse significantly inhibits cellular recruitment in a
murine model of airway inflammation [49]; furthermore,
administration of 10 μg Met-CCL5 for 3 days (30 μg in
total) at the peak of liver fibrosis significantly inhibits fi-
brosis progression and accelerates its regression in chronic
liver diseases [51]. In our study, administration of low
dose Met-CCL5 (2 μg daily; 20 μg for aG-infected or
30 μg for HN10-infected adult mice in total) was enough
to inhibit RABV infection. This might explain why no sig-
nificant difference was observed between low (2 μg) and
high (20 μg) doses of Met-CCL5 treatment.
However, a limited protective role of Met-CCL5 was
observed at the late stage of infection. Considering the
complex pathogenic reasons for the lethal RABV infec-
tion, no single therapeutic reagent is likely to be effect-
ive. Therefore, it is crucial to consider a combination ofMet-CCL5 therapy with other treatments to improve
protection against RABV. Efforts aimed at developing
successful therapeutics to combat RABV infection have
been in progress for decades. Despite attempts at drug
development and antiviral regimens, there are still no ef-
fective treatments for use in the clinic. Several reports
have suggested that RABV neutralizing monoclonal anti-
body cocktails could protect mice from a lethal dose of
RABV infection [52,53]. Therefore, if Met-CCL5 treat-
ment could open a therapeutic window at the early
stage, it would be fundamental to further investigate
whether Met-CCL5 and the RABV neutralizing mono-
clonal antibody cocktails could be used as a combined
therapy to protect the host from RABV infection.
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